These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37957061)

  • 1. Binary subclassification scheme (AUS-Nuclear versus AUS-Other) adequately risk-stratifies thyroid fine needle aspiration specimens classified as Atypia of Undetermined Significance.
    Guzmán-Arocho YD; VanderLaan PA; Nishino M
    J Am Soc Cytopathol; 2024; 13(1):23-32. PubMed ID: 37957061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance.
    Onken AM; VanderLaan PA; Hennessey JV; Hartzband P; Nishino M
    Cancer Cytopathol; 2021 Dec; 129(12):947-955. PubMed ID: 34314102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
    Hall EA; Hartzband P; VanderLaan PA; Nishino M
    Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the rate of malignancy for atypia of undetermined significance subcategories.
    Hang JF; Westra WH; Zhou AG; Cooper DS; Ali SZ
    Cancer Cytopathol; 2018 May; 126(5):309-316. PubMed ID: 29424960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
    Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
    Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules.
    Strickland KC; Howitt BE; Barletta JA; Cibas ES; Krane JF
    Cancer Cytopathol; 2018 Feb; 126(2):86-93. PubMed ID: 28914983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
    Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
    Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
    Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
    Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
    Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
    Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
    Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
    Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
    Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
    Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN.
    Li W; Sciallis A; Lew M; Pang J; Jing X
    Diagn Cytopathol; 2018 Feb; 46(2):148-153. PubMed ID: 29193839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 3rd Edition of the Bethesda System for Reporting Thyroid Cytopathology on Grey Zone Categories.
    Guerreiro SC; Tastekin E; Mourao M; Loureiro I; Eusebio R; Marques HP; Oznur M; Caliskan CK; Schmitt FC; Bongiovanni M; Canberk S
    Acta Cytol; 2023; 67(6):593-603. PubMed ID: 37899024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk of malignancy in cases with atypia of undetermined significance on fine needle aspiration of thyroid nodules even after exclusion of NIFTP.
    Özkara SK; Bayrak BY; Turan G
    Diagn Cytopathol; 2020 Nov; 48(11):986-997. PubMed ID: 32745375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy.
    Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY
    Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of "atypia" in thyroid fine-needle aspiration specimens.
    Kim TH; Krane JF
    Diagn Cytopathol; 2022 Apr; 50(4):146-153. PubMed ID: 34432388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
    Hyeon J; Ahn S; Shin JH; Oh YL
    Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries.
    Bychkov A; Keelawat S; Agarwal S; Jain D; Jung CK; Hong S; Lai CR; Satoh S; Kakudo K
    Pathology; 2018 Jun; 50(4):411-417. PubMed ID: 29631726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RISK OF MALIGNANCY IN THYROID CYTOLOGY: THE IMPACT OF THE RECLASSIFICATION OF NONINVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP).
    Ventura M; Melo M; Fernandes G; Carrilho F
    Endocr Pract; 2019 Jul; 25(7):642-647. PubMed ID: 30865528
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.